Jacqueline Barrientos, MD, MS, discusses the role of non-covalent BTK inhibitors in R/R CLL and provided concise comments on the latest data, including insights from the ongoing BRUIN and Bellwave trials.
Naumann Dives into Case-by-Case Decision-Making in Ovarian and Endometrial Cancer
Revisit the OncLive On Air Episodes From February 2024
Naumann Spotlights Expanding Arsenals and Evolving Decision-Making in Platinum-Resistant Ovarian Cancer
Eskander Emphasizes the Importance of Inclusivity and Accessibility in Oncology Clinical Trials
Acalabrutinib Yields Long-Term Efficacy in a Pooled Analysis of Higher-Risk CLL
Risk Factors Could Inform BTK Inhibitor and Venetoclax Sequencing in CLL/SLL
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC